Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.015
-0.145 (-12.50%)
May 13, 2025, 4:00 PM - Market closed
Akoya Biosciences Employees
Akoya Biosciences had 205 employees as of December 31, 2024. The number of employees decreased by 125 or -37.88% compared to the previous year.
Employees
205
Change (1Y)
-125
Growth (1Y)
-37.88%
Revenue / Employee
$390,054
Profits / Employee
-$231,868
Market Cap
50.56M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 205 | -125 | -37.88% |
Dec 31, 2023 | 330 | -39 | -10.57% |
Dec 31, 2022 | 369 | 50 | 15.67% |
Dec 31, 2021 | 319 | 150 | 88.76% |
Dec 31, 2020 | 169 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AKYA News
- 1 day ago - Akoya Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 days ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 13 days ago - Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders - Business Wire
- 15 days ago - Quanterix and Akoya Biosciences Announce Amended Merger Agreement - Business Wire
- 19 days ago - Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas - GlobeNewsWire
- 19 days ago - Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - GlobeNewsWire
- 20 days ago - Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore - GlobeNewsWire
- 4 weeks ago - Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Business Wire